Jun 09, 2025
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right
Mar 25, 2025
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
Mar 20, 2025
Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options
Mar 06, 2025
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
Feb 25, 2025
Elevation Oncology to Participate in Upcoming Investor Conferences
Dec 05, 2024
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024
Nov 26, 2024
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference
Sep 23, 2024
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
Jun 27, 2024
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
May 07, 2024
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
May 07, 2024
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
May 02, 2024
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
Apr 08, 2024
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Mar 06, 2024
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
Feb 28, 2024
Elevation Oncology to Participate in Upcoming Investor Conferences
Jan 22, 2024
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
Nov 18, 2020
Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
Oct 26, 2020
Elevation Oncology Announces the Presentation of Preclinical Data on the Specific Inhibition of HER3 with Seribantumab to Block NRG1 Fusion Signaling
Sep 16, 2020
Ashion Analytics announces innovative cancer treatment partnership with Elevation Oncology
Aug 11, 2020
Caris Life Sciences Partners with Elevation Oncology to Advance Enrollment in Phase 2 Trial of Patients with Solid Tumors Harboring NRG1 Gene Fusions